Saxagliptin: A clinical review in the treatment of type 2 diabetes mellitus

Clinical Therapeutics

Volumn 33, Issue 8, 2011, Pages 1005-1022

  Kania, Deanna S ^a,b   Gonzalvo, Jasmine D ^a,c   Weber, Zachary A ^a,c  

^a PURDUE UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c WISHARD HEALTH SERVICES   (United States)

Author keywords

Dipeptidyl peptidase 4 inhibitors; Glucagon like peptide 1; Saxagliptin; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATAZANAVIR; CLARITHROMYCIN; CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DILTIAZEM; DIPEPTIDYL PEPTIDASE I; DIPEPTIDYL PEPTIDASE IV; GLIBENCLAMIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; GLYCOPROTEIN P; GLYCOSYLATED HEMOGLOBIN; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; METFORMIN; NEFAZODONE; NELFINAVIR; PIOGLITAZONE; PLACEBO; RITONAVIR; SAQUINAVIR; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TELITHROMYCIN; UNINDEXED DRUG; VILDAGLIPTIN;

ADD ON THERAPY; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BIOSIS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG USE; ELDERLY CARE; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; HEADACHE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; RHINOPHARYNGITIS; SEX DIFFERENCE; SINGLE DRUG DOSE; SPLENOMEGALY; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADAMANTANE; ANIMALS; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 80051654526     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.06.016     Document Type: Article

References (73)

1. National diabetes fact sheet: general information and national estimates on diabetes in the United States Centers for Disease Control and Prevention, Accessed February 25, 2010. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf.
2. Economic costs of diabetes in 2007. Diabetes Care 2008, 31:596-615.
3. Resnick H., Foster G., Bardsley J., Ratner R. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002. The National Health and Nutrition Examination Survey. Diabetes Care 2006, 29:531-537.
4. Koro C.E., Bowlin S.J., Bourgeois N., Fedder D.O. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004, 27:17-20.
5. Heine R., Diamant M., Mbanya J., Nathan D. Management of hyperglycemia in type 2 diabetes. BMJ 2006, 333:1200-1204.
6. Holman R. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metab Clin Exp 2006, 55:S2-S5.
7. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
8. Palalau A.I., Tahrani A.A., Piya M.K., Barnett A.H. DPP-4 inhibitors in clinical practice. Postgrad Med 2009, 121:70-100.
9. Ahren B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin Emerg Drugs 2008, 13:593-607.
10. Drab S.R. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 2010, 30:609-624.
11. Neumiller J.J., Wood L., Campbell R.K. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2010, 30:463-484.
12. Unger J. Choosing among the incretin agents and why it matters. J Fam Pract 2010, 59:S30-S35.
13. Del Prato S., Penno G., Miccoli R. Changing the treatment paradigm for type 2 diabetes. Diabetes Care 2009, 32:S217-S222.
14. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes National Institute for Health and Clinical Excellence, Accessed June 15, 2011. http://www.nice.org.uk/CG87shortguideline.
15. Drug details US Food and Drug Administration, Accessed June 15, 2011. http://www.accessdata.fda.gov.
16. Neumiller J. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc 2009, 49(2003):S16-S29.
17. Onglyza (saxagliptin) 2009, [prescribing information], Bristol-Myers Squibb, Princeton, NJ.
18. Augeri D.J., Robl J.A., Betebenner D.A., et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005, 48:5025-5037.
19. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
20. Fura A., Khanna A., Vyas V., et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos 2009, 37:1164-1171.
21. Scheen A.J. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010, 12:648-658.
22. Dhillon S., Weber J. Saxagliptin. Drugs 2009, 69:2105-2114.
23. Boulton D.W., Geraldes M. Safety, tolerability, pharmacokinetics and pharmacodynamics of once daily oral doses of saxagliptin for 2 weeks in type2 diabetic and healthy subjects. Diabetes 2007, 56(Suppl 1):AI61.
24. Tahrani A.A., Piya M.K., Barnett A.H. Saxagliptin: a new DPP-IV inhibitor for the treatment of type 2 diabetes. Adv Ther 2009, 26:249-262.
25. Kushner P., Gorrell M. DPP-IV Inhibitors in type 2 diabetes: importance of selective enzyme inhibition and implications for clinical use Accessed June 15, 2011. http://www.jfponline.com/Pages.asp?AID=8408.
26. Lankas G.R., Leiting B., Roy R.S., et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidase 8 and 9. Diabetes 2005, 54:2988-2994.
27. Patel C.G., Zhang J., Li L., et al. Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects. J Clin Pharmacol 2010, 50:1211-1216.
28. Boulton D.W., Frevert E.U., Tang A., et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet 2011, 50:253-265.
29. Boulton D.W., Goyal A., Li L., et al. The effects of age and gender on the single dose pharmacokinetics and safety of saxagliptin in healthy subjects. Diabetes 2008, 57(Suppl 1):A164.
30. Deacon C.F., Holst J.J. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther 2009, 26:488-499.
31. Scheen A.J. Dipeptidylpeptitase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet 2010, 49:573-588.
32. Patel C.G., Kornhauser D., Vachharajani N., et al. Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of 3 oral antidiabetic drugs (metformin, glyburide, or pioglitazone) in healthy subjects. Diabetes Obes Metab 2011, 13:604-614.
33. Girgis S., Patel C.G., Li L., et al. Effect of diltiazem on the pharmacokinetics of saxagliptin in healthy subjects. J Clin Pharmacol 2007, 47:1199.
34. Boulton D.W., Brenner E., Royzman K., et al. Effect of ketoconazole on the pharmacokinetics of saxagliptin in healthy subjects. J Clin Pharmacol 2007, 47:1203. Abstract.
35. Rosenstock J., Sankoh S., List J.F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes Obes Metab 2008, 10:376-386.
36. Rosenstock J., Aguiler-Salinas C., Klein E., et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009, 25:2401-2411.
37. Jadzinsky M., Pfutzner A., Paz-Pacheco E., et al. Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009, 11:611-622.
38. Pfutzner A., Paz-Pacheco E., Allen E.M., et al. Initial combination therapy with saxagliptin and metformin provides sustained glycemic control and is well tolerated for up to 76 weeks. Diab Obes Metab 2011, 13:567-576.
39. DeFronzo R.A., Hissa M.N., Garber A.J., et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009, 32:1649-1655.
40. Goke B., Gallwitz B., Eriksson J., et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomized controlled trial. Int J Clin Pract 2010, 64:1619-1631.
41. Chacra A.R., Tan G.H., Apanovitch A., et al. Saxagliptin added to submaximal dose of sulphonylurea improves glycemic control compared to uptitration of sulphonylurea in patients with type 2 diabetes: a randomized controlled trial. Int J Clin Pract 2009, 63:1395-1406.
42. Hollander P., Li J., Allen E., Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009, 94:4810-4819.
43. Scheen A.J., Charpentier G., Ostgren C.J., et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010, 26:540-549.
44. Stenlof K., Raz I., Neutel J., et al. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin 2010, 26:2355-2363.
45. DeFronzo R., Hissa M.N., Garber A.J., et al. Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes mellitus. Diabetes 2009, 58(Suppl 1).
46. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Eng J Med 2007, 356:2457-2471.
47. Nowicki M., Rychlik I., Haller H., et al. Saxagliptin improves glycemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab 2011, 13:523-532.
48. Lup R., Del Prato S. Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences. Diabetes Metab 2008, 34(Suppl 2):S56-S64.
49. Prentki M., Nolan C.J. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006, 116:1802-1812.
50. Bulotta A., Hui H., Anastasi E., et al. Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1. J Mol Endocrinol 2002, 29:347-360.
51. Farilla L., Bulotta A., Hirshberg B., et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003, 144:5149-5158.
52. Kirby M., Yu D.M.T., O'Connor S.P., et al. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci 2010, 118:31-41.
53. Yazbeck R., Howarth G.S., Abbott C.A. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?. Trends Pharmacol Sci 2009, 30:600-607.
54. Andukuri R., Drincic A., Rendell M. Alogliptin: a new addition to the DPP-4 inhibitors. Diabetes Metab Syndr Obes 2009, 2:117-126.
55. Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes US Department of Health and Human Services, Food and Drug Administration, Accessed June 15, 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf.
56. Frederich R., Alexander J.H., Fiedorek F.T., et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010, 122:16-27.
57. Chen R., Donovan M., Rusnak J.M. Saxagliptin used as monotherapy or in combination with other antihyperglycemic agents does not significantly increase risk of hypoglycemia. Diabetes 2009, 58:2082-P.
58. Aschner P., Kipnes M.S., Lunceford J.K., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632-2637.
59. Raz I., Hanefeld M., Xu L., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006, 49:2564-2571.
60. Charbonnel B., Karasik A., Liu J., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29:2638-2643.
61. Rosenstock J., Brazg R., Andryuk P.J., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006, 28:1556-1568.
62. Hermansen K., Kipnes M., Luo E., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007, 9:733-745.
63. Goldstein B.J., Feinglos M.N., Lunceford J.K., et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30:1979-1987.
64. Ristic S., Bylers S., Foley J., Holmes D. Improved glycemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin dose response. Diabetes Obes Metab 2005, 7:692-698.
65. Ahren B., Pacini G., Foley J.E., Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005, 28:1936-1940.
66. Rosenstock J., Kim S.W., Baron M.A., et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007, 9:175-185.
67. Garber A.J., Schweizer A., Baron M.A., et al. Vildagliptin in combination with pioglitazone improves glycemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007, 9:155-174.
68. DeFronzo R.A., Fleck P.R., Wilson C.A., Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008, 31:2315-2317.
69. Del Prato S., Barnett A.H., Huisman H., et al. Effect of linagliptin monotherapy on glycemic control and markers of B-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011, 13:258-267.
70. Taskinen M.R., Rosenstock J., Tamminen I., et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011, 13:65-74.
71. Rodbard H.W., Jellinger P.S., Davidson J.A., et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel of type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009, 15:540-559.
72. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008, 32(Suppl 1):S1-S201. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee.
73. Gerich J. DPP-4 inhibitors: what may be the clinical differentiators?. Diab Res Clin Pract 2010, 90:131-140.